Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy.
Di Lorenzo A, Bolli E, Ruiu R, Ferrauto G, Di Gregorio E, Avalle L, Savino A, Poggio P, Merighi IF, Riccardo F, Brancaccio M, Quaglino E, Cavallo F, Conti L.
Di Lorenzo A, et al. Among authors: cavallo f.
Oncoimmunology. 2022 Jun 15;11(1):2086752. doi: 10.1080/2162402X.2022.2086752. eCollection 2022.
Oncoimmunology. 2022.
PMID: 35756841
Free PMC article.